A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada
DOI:
https://doi.org/10.5489/cuaj.9110Keywords:
Non muscle invasive bladder cancer, TURBT, BCG, Outcomes, Survival, Intravesical therapyAbstract
INTRODUCTION: Approximately three-quarters of patients newly diagnosed with bladder cancer have non-muscle-invasive disease (NMIBC). Among these patients, those with high-risk (HR) features should be managed more aggressively in an attempt to circumvent the elevated risk of recurrence/progression. Population-based data on the incidence of HR-NMIBC and receipt of guideline-recommended care are limited.
METHODS: This retrospective, observational study gathered data from multiple linked provincial (Alberta) healthcare databases to describe baseline characteristics, treatment patterns, and survival outcomes in a population of individuals diagnosed with HR-NMIBC from 2010-2020. Data for all patients aged >18 years with T1, Tis, or high-grade Ta NMIBC (“high-risk”) were analyzed using basic statistics, multivariate regression analyses, and the Kaplan-Meier method.
RESULTS: Of 6837 de novo NMIBC patients identified, 3874 (57%) were categorized as HR-NMIBC. The majority (82%) were male with a median age of 72 years, and approximately half had a Charlson comorbidity index score ≥1. Following initial transurethral resection of bladder tumor (TURBT), 61% of the cohort received no adjuvant bacillus Calmette-Guérin (BCG) or chemotherapy, while 36% received BCG, 3% gemcitabine, and 1% mitomycin C. Patients underwent a median of four TURBT procedures. ‘Adequate BCG’ (≥5 induction doses + ≥2 maintenance doses) was received by 32% of BCG-treated and 12% of all HR-NMIBC patients. Survival was improved in patients receiving adequate BCG.
CONCLUSIONS: Data from this large, real-world population highlights poor use of induction/ maintenance BCG therapy following TURBT among patients with HR-NMIBC.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
